<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Harmony Biosciences Holdings — News on 6ix</title>
<link>https://6ix.com/company/harmony-biosciences-holdings</link>
<description>Latest news and press releases for Harmony Biosciences Holdings on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 12:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/harmony-biosciences-holdings" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68357f7278dffbe2df0fb068.webp</url>
<title>Harmony Biosciences Holdings</title>
<link>https://6ix.com/company/harmony-biosciences-holdings</link>
</image>
<item>
<title>Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026</title>
<link>https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-to-report-first-quarter-2026-financial-results-on-may-7-2026</link>
<guid isPermaLink="true">https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-to-report-first-quarter-2026-financial-results-on-may-7-2026</guid>
<pubDate>Thu, 23 Apr 2026 12:05:00 GMT</pubDate>
<description>PLYMOUTH MEETING, Pa., April 23, 2026--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on May 7, 2026, at 8:30 a.m. ET to discuss the results.</description>
</item>
<item>
<title>Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting</title>
<link>https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-to-present-open-label-extension-data-from-phase-3-argus-trial-at-the-2026-american-academy-of-neurology-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-to-present-open-label-extension-data-from-phase-3-argus-trial-at-the-2026-american-academy-of-neurology-annual-meeting</guid>
<pubDate>Thu, 16 Apr 2026 12:05:00 GMT</pubDate>
<description>PLYMOUTH MEETING, Pa., April 16, 2026--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore open-label extension data from the company’s investigation of EPX-100 (clemizole hydrochloride) in the ongoing Phase 3 ARGUS trial for the treatment of Dravet syndrome at the 2026 American Academy of Neurology Annual Meeting being held April 18 – 22 in Chicago, IL.</description>
</item>
<item>
<title>Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer</title>
<link>https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-appoints-glenn-reicin-as-chief-financial-officer</link>
<guid isPermaLink="true">https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-appoints-glenn-reicin-as-chief-financial-officer</guid>
<pubDate>Tue, 14 Apr 2026 04:00:00 GMT</pubDate>
<description>COMPANY REITERATES ITS 2026 NET REVENUE GUIDANCE OF OVER $1 BILLION IN WAKIX SALES PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)-- Harmony Biosciences Holdings,</description>
</item>
<item>
<title>Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board</title>
<link>https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-strengthens-executive-team-with-new-appointment-and-announces-additions-to-its-board-114</link>
<guid isPermaLink="true">https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-strengthens-executive-team-with-new-appointment-and-announces-additions-to-its-board-114</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Appointments support Harmony’s next phase of growth and long‑term value creation PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)-- Harmony Biosciences Holdings, Inc.</description>
</item>
<item>
<title>Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-to-participate-in-25th-annual-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-to-participate-in-25th-annual-needham-virtual-healthcare-conference</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that Harmony's management team will participate in</description>
</item>
<item>
<title>Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion</title>
<link>https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-reports-strong-2025-financial-results-and-reiterates-2026-net-revenue-guidance-of-over-dollar1-billion</link>
<guid isPermaLink="true">https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-reports-strong-2025-financial-results-and-reiterates-2026-net-revenue-guidance-of-over-dollar1-billion</guid>
<pubDate>Tue, 24 Feb 2026 12:30:00 GMT</pubDate>
<description>PLYMOUTH MEETING, Pa., February 24, 2026--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced earnings with reported revenue of $243.8 million for Q4 2025, representing 21% year-over-year revenue growth for WAKIX®. For the full year 2025, the company generated $868.5 million in net product revenue, reflecting continued commercial strength as evidenced by six consecutive years of revenue growth and profitability. The company enters the year with significant momentum, reinforcing its</description>
</item>
<item>
<title>Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy</title>
<link>https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-receives-u-food-130500651</link>
<guid isPermaLink="true">https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-receives-u-food-130500651</guid>
<pubDate>Tue, 17 Feb 2026 13:05:00 GMT</pubDate>
<description>PLYMOUTH MEETING, Pa., February 17, 2026--Harmony Biosciences (Nasdaq: HRMY) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) for WAKIX® (pitolisant) tablets for the treatment of cataplexy in pediatric patients 6 years of age and older with narcolepsy. WAKIX is now the first-and-only FDA-approved non-scheduled treatment for pediatric and adult narcolepsy patients with or without cataplexy.</description>
</item>
<item>
<title>Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026</title>
<link>https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-report-fourth-quarter-130500089</link>
<guid isPermaLink="true">https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-report-fourth-quarter-130500089</guid>
<pubDate>Tue, 10 Feb 2026 13:05:00 GMT</pubDate>
<description>PLYMOUTH MEETING, Pa., February 10, 2026--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on February 24, 2026, at 8:30 a.m. ET to discuss the results.</description>
</item>
<item>
<title>Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation</title>
<link>https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-guides-over-1-130500263</link>
<guid isPermaLink="true">https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-guides-over-1-130500263</guid>
<pubDate>Mon, 12 Jan 2026 13:05:00 GMT</pubDate>
<description>PLYMOUTH MEETING, Pa., January 12, 2026--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced strong preliminary, unaudited net product revenue for Q4 and full year 2025 of approximately $243 million and $868 million, respectively. The company continues to build on six consecutive years of revenue growth. On track to extend the pitolisant franchise, Harmony fortifies its profile as a profitable, self-funding biotech company with a robust, late-stage pipeline and strong long-term gro</description>
</item>
<item>
<title>Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-present-44th-annual-130500162</link>
<guid isPermaLink="true">https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-present-44th-annual-130500162</guid>
<pubDate>Wed, 07 Jan 2026 13:05:00 GMT</pubDate>
<description>PLYMOUTH MEETING, Pa., January 07, 2026--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced its participation in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Jeffrey M. Dayno, M.D., President and Chief Executive Officer, is scheduled to present at the conference on Tuesday, January 13, 2026, at 4:30 p.m. PT / 7:30 p.m. ET.</description>
</item>
<item>
<title>Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG</title>
<link>https://6ix.com/company/harmony-biosciences-holdings/news/beacon-biosignals-announces-partnership-with-harmony-biosciences-to-advance-objective-clinical-endpoints-in-hypersomnia-conditions-through-quantitative-eeg</link>
<guid isPermaLink="true">https://6ix.com/company/harmony-biosciences-holdings/news/beacon-biosignals-announces-partnership-with-harmony-biosciences-to-advance-objective-clinical-endpoints-in-hypersomnia-conditions-through-quantitative-eeg</guid>
<pubDate>Tue, 16 Dec 2025 11:30:00 GMT</pubDate>
<description>BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Beacon Biosignals, a leader in AI-driven neurophysiology and precision drug development, today announced a collaboration with Harmony Biosciences (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for rare neurological disorders, to incorporate quantitative electroencephalography (EEG) measurements into two of Harmony’s Phase 3 studies of HBS-301 for Narcolepsy and Idiopathic Hypersomnia. The collabo</description>
</item>
<item>
<title>Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome</title>
<link>https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-presents-clinically-meaningful-open-label-extension-study</link>
<guid isPermaLink="true">https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-presents-clinically-meaningful-open-label-extension-study</guid>
<pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
<description>Data presented at the 2025 American Epilepsy Society Annual Meeting PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)-- Harmony Biosciences Holdings, Inc. (Nasdaq:</description>
</item>
<item>
<title>Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting</title>
<link>https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-present-new-open-label-extension-data-phase-3-argus-trial-2025</link>
<guid isPermaLink="true">https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-present-new-open-label-extension-data-phase-3-argus-trial-2025</guid>
<pubDate>Tue, 02 Dec 2025 05:00:00 GMT</pubDate>
<description>PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will highlight new open-label extension</description>
</item>
<item>
<title>Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation</title>
<link>https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-announces-positive-results-pivotal-bioequivalence-study</link>
<guid isPermaLink="true">https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-announces-positive-results-pivotal-bioequivalence-study</guid>
<pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
<description>New Drug Application to be submitted in early 2026; target PDUFA in Q1 2027 Utility patent applications filed with potential exclusivity to 2044 PLYMOUTH</description>
</item>
<item>
<title>Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence</title>
<link>https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-announces-initiation-first-human-study-potential-best-class</link>
<guid isPermaLink="true">https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-announces-initiation-first-human-study-potential-best-class</guid>
<pubDate>Wed, 19 Nov 2025 05:00:00 GMT</pubDate>
<description>BP1.15205 is a differentiated chemical scaffold, demonstrating high potency and selectivity in preclinical studies with a favorable safety profile and the</description>
</item>
<item>
<title>Harmony Biosciences to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-participate-upcoming-investor-conferences-2025-11-18</link>
<guid isPermaLink="true">https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-participate-upcoming-investor-conferences-2025-11-18</guid>
<pubDate>Tue, 18 Nov 2025 05:00:00 GMT</pubDate>
<description>PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate</description>
</item>
<item>
<title>Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M</title>
<link>https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-reports-strong-q3-2025-financial-results-recently-raised-2025</link>
<guid isPermaLink="true">https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-reports-strong-q3-2025-financial-results-recently-raised-2025</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>WAKIX® (pitolisant) Franchise Delivers Net Revenue of $239M in Q3 2025 (+29% YoY Growth) Record Increase in Average Number of Patients of Approximately 500</description>
</item>
<item>
<title>Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance</title>
<link>https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-preannounces-strong-q3-2025-wakix-performance-raises-2025-revenue</link>
<guid isPermaLink="true">https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-preannounces-strong-q3-2025-wakix-performance-raises-2025-revenue</guid>
<pubDate>Thu, 23 Oct 2025 04:00:00 GMT</pubDate>
<description>PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced preliminary results for Q3 2025, highlighted by</description>
</item>
<item>
<title>Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome</title>
<link>https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-provides-update-its-phase-3-reconnect-study-zyn002-fragile-x</link>
<guid isPermaLink="true">https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-provides-update-its-phase-3-reconnect-study-zyn002-fragile-x</guid>
<pubDate>Wed, 24 Sep 2025 04:00:00 GMT</pubDate>
<description>PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced topline results from its Phase 3 registrational</description>
</item>
<item>
<title>Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress</title>
<link>https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-present-rare-epilepsy-data-36th-international-epilepsy-congress</link>
<guid isPermaLink="true">https://6ix.com/company/harmony-biosciences-holdings/news/harmony-biosciences-present-rare-epilepsy-data-36th-international-epilepsy-congress</guid>
<pubDate>Tue, 26 Aug 2025 04:00:00 GMT</pubDate>
<description>PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will present data from its rare epilepsy</description>
</item>
</channel>
</rss>